Opinion|Videos|November 19, 2026

Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial

The panel opens by defining high-risk localized prostate cancer. One panelist looks at Gleason grade, T stage, spread to the seminal vesicles or lymph nodes, and PSA level.

The panel opens by defining high-risk localized prostate cancer. One panelist looks at Gleason grade, T stage, spread to the seminal vesicles or lymph nodes, and PSA level. Another explains that the goal is cure, which can come from surgery, or from radiation with or without the help of systemic therapy. Patients whose PSA stays persistent or rises after surgery may need added treatment. The discussion then turns to the DASL-HiCaP trial, referenced as DASL in this discussion, which is a phase 3 trial of darolutamide added to radiation and ADT in localized high-risk/very high-risk or recurrent disease. It enrolled more than 1100 patients and measured metastasis-free survival on conventional scans. The faculty say metastasis-free survival improved significantly, and one panelist says the data are enough to change practice.


Related to this article